אריוודג' - Erivedge
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01XJ Hedgehog pathway inhibitors | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||||||||||||||
| צ×רת ××× ×× | קפס×××ת, CAPSULES ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | ERIVEDGE® is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation
| ||||||||||||||||||
| |||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
Â
Â
| ||||||||||||||||||
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×ר×××××' ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | HOFFMANN LA ROCHE, SWITZERLAND |
| ×©× ××¢× ×ר×ש×× | ROCHE PHARMACEUTICALS (ISRAEL) LTD |
| ר×ש××× | ת×ר×× ××ש×: 05/2012. ר×ש××× ×ת×ר××: 02/2018 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־14 בספטמבר 2025 ב־05:40